Back to News
Market Impact: 0.38
Nasus Pharma's IND Application For NS002 Gets FDA Clearance
Source: Nasdaq
Healthcare & BiotechProduct LaunchesRegulation & Legislation
Nasus Pharma said the FDA cleared its Investigational New Drug application for NS002, an investigational intranasal epinephrine powder intended to treat anaphylaxis. The clearance enables clinical development of a needle-free epinephrine delivery candidate and is a meaningful positive regulatory milestone for NSRX.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
Ticker Sentiment
NSRX0.82
More News
- Google's Gemini 4 Carbon looks like a diamond in the rough
- Healey Defends UK Budget, Warns 'Tough Decisions' Ahead
- Trump methane policy rollback may have minimal impact on crude prices, EPA says
- Kalshi, co-founders hit with criminal charges in US state of Utah
- Nvidia's $12.9 billion Hugging Face deal draws DOJ scrutiny
- Judge says Trump's bid to set aside California ballots would ‘wreak havoc’ on democracy